DE69534471D1 - Peptide, die fähig sind die sh3-domäne des gap-proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung - Google Patents

Peptide, die fähig sind die sh3-domäne des gap-proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung

Info

Publication number
DE69534471D1
DE69534471D1 DE69534471T DE69534471T DE69534471D1 DE 69534471 D1 DE69534471 D1 DE 69534471D1 DE 69534471 T DE69534471 T DE 69534471T DE 69534471 T DE69534471 T DE 69534471T DE 69534471 D1 DE69534471 D1 DE 69534471D1
Authority
DE
Germany
Prior art keywords
domain
pct
peptides
binding
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534471T
Other languages
English (en)
Other versions
DE69534471T2 (de
Inventor
Marc Duchesne
Didier Faucher
Fabienne Parker
Fabien Schweighoffer
Bruno Tocque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9413955A external-priority patent/FR2727116B1/fr
Priority claimed from FR9505753A external-priority patent/FR2734266B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE69534471D1 publication Critical patent/DE69534471D1/de
Publication of DE69534471T2 publication Critical patent/DE69534471T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C07K14/4706—Guanosine triphosphatase activating protein, GAP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69534471T 1994-11-22 1995-11-22 Peptide, die fähig sind die sh3-domäne des gap-proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung Expired - Lifetime DE69534471T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9413955A FR2727116B1 (fr) 1994-11-22 1994-11-22 Peptides capables de se lier au domaine sh3 de la proteine gap, sequences nucleotidiques codant pour ces peptides, leur preparation et utilisation
FR9413955 1994-11-22
FR9505753A FR2734266B1 (fr) 1995-05-16 1995-05-16 Peptides capables de se lier au domaine sh3 de la proteine gap sequences nucleotidiques codant pour ces peptides, leur preparation et utilisation
FR9505753 1995-05-16
PCT/FR1995/001539 WO1996016169A1 (fr) 1994-11-22 1995-11-22 Peptides capables de se lier au domaine sh3 de la proteine gap, sequences nucleotidiques codant pour ces peptides, leur preparation et utilisation

Publications (2)

Publication Number Publication Date
DE69534471D1 true DE69534471D1 (de) 2006-02-02
DE69534471T2 DE69534471T2 (de) 2006-06-22

Family

ID=26231549

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534471T Expired - Lifetime DE69534471T2 (de) 1994-11-22 1995-11-22 Peptide, die fähig sind die sh3-domäne des gap-proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung

Country Status (18)

Country Link
US (1) US5886150A (de)
EP (1) EP0793721B1 (de)
JP (2) JPH10509044A (de)
AT (1) ATE305037T1 (de)
AU (1) AU713937B2 (de)
BR (1) BR9510067A (de)
CA (1) CA2204438A1 (de)
CZ (1) CZ292538B6 (de)
DE (1) DE69534471T2 (de)
DK (1) DK0793721T3 (de)
ES (1) ES2248800T3 (de)
FI (1) FI972170A0 (de)
HU (1) HU221410B1 (de)
IL (1) IL116026A (de)
MX (1) MX9703364A (de)
NO (1) NO972313D0 (de)
SK (1) SK287034B6 (de)
WO (1) WO1996016169A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780062B1 (fr) * 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
TWI257394B (en) 1998-10-23 2006-07-01 Kirin Amgen Inc Thrombopoietic compounds
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20040022779A1 (en) * 2000-06-16 2004-02-05 Thomas Rudel Method for identifying apoptosis-modified proteins
US7846746B2 (en) * 2001-04-10 2010-12-07 Children's Medical Center Corporation Methods of analysis and labeling of protein-protein interactions
US20050069999A1 (en) * 2001-07-09 2005-03-31 Sharma Sreenath V Sh3 domain binding inhibitors
WO2003006060A1 (fr) * 2001-07-09 2003-01-23 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de la liaison au domaine sh3
AUPR721101A0 (en) * 2001-08-23 2001-09-13 University Of Queensland, The Nucleic acid and polypeptide linked to breast cancer
WO2006010057A2 (en) * 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
BRPI0516011A (pt) * 2004-09-24 2008-08-19 Amgen Inc moléculas fc modificadas
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
US11237168B2 (en) * 2019-06-26 2022-02-01 St. Jude Children's Research Hospital Method for identifying modulators of G3BP activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA894726B (en) * 1988-06-27 1990-03-28 Akzo Nv Coccidiosis vaccine
ATE181332T1 (de) * 1989-08-21 1999-07-15 Chiron Corp Vom gtpase-aktivierenden protein (gap) abgeleitete peptide sowie deren diagnostische und therapeutische verwendung
CA2057675A1 (en) * 1990-12-24 1992-06-25 Michael D. Schaber Peptide inhibitors of ras-gap interaction
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
EP0679185A1 (de) * 1993-01-15 1995-11-02 Schering Corporation Mit ras assoziierte gap-proteine

Also Published As

Publication number Publication date
MX9703364A (es) 1997-08-30
US5886150A (en) 1999-03-23
HUT77029A (hu) 1998-03-02
CZ292538B6 (cs) 2003-10-15
FI972170A (fi) 1997-05-21
DK0793721T3 (da) 2006-01-30
EP0793721A1 (de) 1997-09-10
IL116026A0 (en) 1996-01-31
SK287034B6 (sk) 2009-10-07
AU713937B2 (en) 1999-12-16
BR9510067A (pt) 1997-12-30
ES2248800T3 (es) 2006-03-16
FI972170A0 (fi) 1997-05-21
DE69534471T2 (de) 2006-06-22
CA2204438A1 (fr) 1996-05-30
ATE305037T1 (de) 2005-10-15
NO972313L (no) 1997-05-21
AU4263696A (en) 1996-06-17
SK62997A3 (en) 1998-02-04
EP0793721B1 (de) 2005-09-21
JP2006122049A (ja) 2006-05-18
IL116026A (en) 2005-08-31
HU221410B1 (en) 2002-09-28
JPH10509044A (ja) 1998-09-08
CZ154597A3 (en) 1997-10-15
NO972313D0 (no) 1997-05-21
WO1996016169A1 (fr) 1996-05-30

Similar Documents

Publication Publication Date Title
ATE544776T1 (de) Chimäre dna-bindeproteine
FI962247A (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
DE69534471D1 (de) Peptide, die fähig sind die sh3-domäne des gap-proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
BR9710919A (pt) Proteina purificada sr-p70
BR9910787A (pt) Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src
SE9602822D0 (sv) New receptor
PT1141305E (pt) Gene quimerico formado pelas sequencias de adn que codifica os determinantes antigenicos de quatro proteinas de l. infantum
ATE215123T1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
ZA982009B (en) Isolated nucleic acid molecules encoding SSX family members and uses thereof.
DE69529235T2 (de) Menschliche dnase i varianten
SE9604439D0 (sv) New receptor
WO2002059149A3 (en) Pro-apoptotic proteins and dna molecules encoding them
GB2329896A (en) Enzyme and DNA sequence encoding same
WO2002070560A3 (en) Nuclear hormone receptor ligand binding domain
BG101847A (en) Human dnase i variants

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC